Genetic Technologies Limited operates as a biotechnology company. BREVAGen The company offers a proprietary breast cancer risk assessment test named BREVAGen. In addition to the BREVAGen test, the company owns a suite of patents valid to 2022, which augment and extend the company’s non-coding patent portfolio. In 2010, the company incorporated a wholly-owned subsidiary named Phenogen Sciences Inc. in the state of Delaware, which commenced selling the BREVAGen test in the U.S. marketplace in 2011. In 2014, the company announced the U.S. release of BREVAGenplus, a predictive risk test for various women at risk of developing sporadic, or non-hereditary, breast cancer, representing a marked enhancement in patient applicability, over the company’s first generation BREVAGen product. BREVAGenplus is a clinically validated, predictive risk test for sporadic breast cancer which examines a woman’s clinical risk factors, combined with 77 scientifically validated genetic biomarkers, to allow for more personalized breast cancer risk assessment and risk management. The strategic alliance with Myriad Genetics Inc. delivered to the company exclusive rights in Australia and New Zealand to perform DNA testing for susceptibility to a range of cancers. The company would continue to pursue out-licensing/co-development partnering options for the RareCellect Project. Environmental Regulations The company’s operations are subject to environmental regulations under Australian State legislation. In particular, the company is subject to the requirements of the Environment Protection Act 1993. Dispositions In 2014, the company completed the sale of its heritage Australian Genetics business to Specialist Diagnostic Services Ltd. Strategy As part of the company’s strategy to focus on the expansion of its cancer diagnostic franchise, the company continues to evaluate opportunities to sell, out-license or co-develop other assets and technologies in which the company has an interest, including its legacy non-coding assertion and licensing program. History Genetic Technologies Limited was founded in 1989.
genetic tech ltd-sp adr (GENE:NASDAQ CM)
60-66 Hanover Street
Fitzroy, VIC 3065
Phone: 61 3 8412 7000
Fax: 61 3 8412 7040www.gtglabs.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for GENE.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact GENETIC TECH LTD-SP ADR, please visit www.gtglabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.